Last updated: February 20, 2026
What is the Drug Associated with NDC 00143-9857?
NDC 00143-9857 references a drug product manufactured by Teva Pharmaceuticals. It is identified as Dextroamphetamine Sulfate Tablets, 5 mg. This medication is primarily used for treating Attention Deficit Hyperactivity Disorder (ADHD) and Narcolepsy.
Market Size and Demand Drivers
Current Market Size
- Global ADHD drug market: $13.8 billion in 2022, expected to grow at a CAGR of 6.7% through 2030 (Grand View Research).
- U.S. market share: Approximately 70% of global ADHD medication sales, estimated at $9.66 billion in 2022 (IQVIA).
Key Demand Factors
- Increasing diagnosis rates: ADHD diagnoses in children in the U.S. reached 9.4% in 2020, across 6.4 million children (CDC).
- Off-label use: Some adult populations use stimulant medications for focus and productivity.
- Treatment adherence: Available in generic forms, leading to stable demand.
Competition Landscape
- Major competitors include brands like Adderall (mixed amphetamine salts), Vyvanse (lisdexamfetamine), and generic formulations.
- Market penetration of generics: Over 60% of prescriptions for ADHD medications are for generics, intensifying price competition.
Pricing Trends and Projections
Current Pricing
- Average wholesale price (AWP): Approximately $0.25 per tablet for Dextroamphetamine 5 mg (as per FirstDatabank, 2023).
- Typical retail price: Between $1.00 and $2.50 per tablet, depending on the pharmacy and insurance coverage.
Historical Price Trends
| Year |
Average Price per Tablet |
Notes |
| 2018 |
$0.40 |
Stable pricing, limited generic competition |
| 2020 |
$0.30 |
Entry of additional generics, slight decrease |
| 2022 |
$0.25 |
Increased generic market share, price compression |
Price Projection for 2024–2028
- Expect prices to stabilize around $0.20–$0.30 per tablet.
- Price declines of up to 20% from 2022 levels anticipated, driven by increased generics and payer pressure.
- Potential premium for specific formulations (e.g., branded or extended-release versions) could sustain higher prices in select channels.
Regulatory and Policy Impact
- FDA Approval: Dextroamphetamine is a Schedule II controlled substance, facing strict prescribing regulations.
- Patent and exclusivity: The drug is in the generic market phase, with no recent patent protection.
- Policy trends: Rising scrutiny on stimulant misuse and abuse could influence prescribing patterns, but no immediate impact on pricing is anticipated.
Market Entry Barriers for Competitors
- Strict regulatory compliance and controlled substance security.
- Existing large-scale manufacturing and distribution networks.
- Established prescribing habits among physicians and insurance formularies.
Investment and Commercialization Implications
- Slight downward price pressure expected; volume growth for prescriptions is a primary growth driver.
- Expanding access and diagnosis rates contribute to continued demand.
- Generic competition limits profitability for new entrants unless differentiated by formulation or delivery method.
Summary Table: Price Outlook Summary (2023–2028)
| Year |
Projected Price Range per Tablet |
Key Factors |
| 2023 |
$0.23–$0.25 |
Market stability, existing competition |
| 2024 |
$0.20–$0.23 |
Increased generic entries, payer pressure |
| 2025 |
$0.20–$0.22 |
Continued generics, stable demand |
| 2026 |
$0.20–$0.21 |
Market saturation, generic dominance |
| 2027 |
$0.20 |
Pricing plateau, volume-based growth |
Key Takeaways
- NDC 00143-9857 corresponds to generic Dextroamphetamine Sulfate 5 mg tablets, with a stable but declining price trend.
- Market size driven by rising ADHD diagnosis and increased generic supply.
- Price compression expected due to competitive pressures, with minor potential for premium pricing for specialized formulations.
- Regulatory and policy factors support stable demand but may impose prescribing restrictions.
FAQs
Q1: How does the generic status of this drug affect its market price?
Generics lead to lower prices due to increased competition, reducing profitability for manufacturers and limiting retail prices.
Q2: Are there regional price variations for this medication?
Yes; prices differ based on pharmacy discounts, insurance coverage, and regional regulations.
Q3: What are the primary competitors for this generic drug?
Adderall and Vyvanse are the main competitors, along with other amphetamine-based therapy options.
Q4: Will new formulations influence the price of this drug?
Extended-release or novel delivery systems could command higher prices but are not expected to significantly impact the 5 mg tablet segment.
Q5: How might policy changes impact the market?
Stricter controls on prescribing stimulants could limit volume growth, but current demand trends suggest continued steady use.
References
- Grand View Research. (2023). ADHD drugs market size, share, insights. Retrieved from https://www.grandviewresearch.com
- IQVIA. (2023). U.S. prescription drug market analysis. Retrieved from https://www.iqvia.com
- CDC. (2020). ADHD prevalence and diagnosis statistics. Retrieved from https://www.cdc.gov
- FirstDatabank. (2023). Drug pricing and formulary data.
- U.S. Food and Drug Administration. (2022). Controlled substances scheduling. Retrieved from https://www.fda.gov
